Related Experiment Video

Updated: May 4, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K

Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression

Dong Li1, Kun Xie1, Guitao Ding1

  • 1School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.

Cancer Letters
|December 17, 2013
PubMed

Insights

Tumors can become resistant to anti-VEGF cancer therapy by activating the VEGF-C pathway. Inhibiting VEGF-C can partially restore sensitivity to VEGF inhibitors, offering a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prolonged use of anti-vascular endothelial growth factor (VEGF) agents in cancer therapy can lead to tumor resistance.
  • Understanding the molecular mechanisms of this resistance is crucial for developing more effective treatments.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying resistance to anti-VEGF therapy.
  • To identify potential pathways involved in the development of resistance to VEGF inhibitors.

Main Methods:

  • Development of a VEGF inhibitor-resistant Lewis lung carcinoma (LLC) cell line through in vivo selection.
  • RNA-sequencing (RNA-seq) analysis to compare transcriptome profiles of resistant and non-resistant tumor cells.
  • Quantitative real-time PCR and immunohistochemical analyses to validate gene expression changes.

Main Results:

  • Vascular endothelial growth factor C (VEGF-C) was significantly up-regulated in resistant tumor cells compared to non-resistant cells.
  • Inhibition of VEGF-C in resistant cells suppressed endothelial cell migration in vitro.
  • Inhibition of VEGF-C partially restored the sensitivity of resistant cells to VEGF-Trap treatment in vivo.

Conclusions:

  • Tumors may develop resistance to anti-VEGF therapy by activating the VEGF-C pathway.
  • Targeting the VEGF-C pathway could be a strategy to overcome or prevent resistance to anti-VEGF cancer therapies.
Keywords:
AngiogenesisAnimal modelDrug resistanceLung carcinomaRNA-seqVEGF

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

120
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

9.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K